Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration

Completed

Conditions studied: Spinal Muscular Atrophy

In brief

This is an observational study to investigate the improvement of NMJ defects in adult patients with SMA following treatment with Risdiplam. Eligible patients will have received treatment with daily oral Risdiplam after receiving approval through their commercial insurance or drug assistance program. All subjects will be evaluated at one visit. Eligible subjects must have been receiving risdiplam for at least 12 months.

Key facts

Study ID
NCT05219487
Run by
Bakri Elsheikh
People needed
18
Starts
2021-10-13
Expected to finish
2025-12-31
Last updated by the study team
2026-02-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.